Precision BioSciences, Inc.
TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES

Last updated:

Abstract:

Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.

Status:
Application
Type:

Utility

Filling date:

17 Jul 2020

Issue date:

7 Jan 2021